Mundipharma Research Limited clinical trials

A subsidiary of Mundipharma

The registry lists 36 studies whose lead sponsor is Mundipharma Research Limited. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated May 14, 2026.

Studies

Recruiting first, then most recently updated. Showing 36 of 36. All Mundipharma studies →

• Rezafungin for Treatment of Pneumocystis Pneumonia in HIV AdultsRecruitingNCT05835479Phase 2

  Sponsor listed in the registry: Mundipharma Research Limited

• Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment OptionsActive, not recruitingNCT06794554Phase 2

  Sponsor listed in the registry: Mundipharma Research Limited

• Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow TransplantationCompletedNCT04368559Phase 3

  Sponsor listed in the registry: Mundipharma Research Limited

• Study of Tinostamustine for Adjuvant Treatment of GlioblastomaCompletedNCT05432375Early Phase 1

  Sponsor listed in the registry: Mundipharma Research Limited

• Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of AgeTerminatedNCT05534529Phase 1

  Sponsor listed in the registry: Mundipharma Research Limited

• Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.CompletedNCT03345485Phase 1/2

  Sponsor listed in the registry: Mundipharma Research Limited

• Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic MalignanciesCompletedNCT02576496Phase 1

  Sponsor listed in the registry: Mundipharma Research Limited

• A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPDCompletedNCT01946620Phase 3

  Sponsor listed in the registry: Mundipharma Research Limited

• Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible AsthmaCompletedNCT00476073Phase 3

  Sponsor listed in the registry: Mundipharma Research Limited

• Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric PatientsCompletedNCT01511367Phase 3

  Sponsor listed in the registry: Mundipharma Research Limited

• A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMRTerminatedNCT01821040Phase 3

  Sponsor listed in the registry: Mundipharma Research Limited

• A Study to Characterize the Pharmacokinetics and Tolerability of Buprenorphine Patches in Children With Moderate to Severe Mouth PainTerminatedNCT00947466Phase 1/2

  Sponsor listed in the registry: Mundipharma Research Limited

• Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years.CompletedNCT02063139Phase 2

  Sponsor listed in the registry: Mundipharma Research Limited

• Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe AsthmaCompletedNCT00734318Phase 3

  Sponsor listed in the registry: Mundipharma Research Limited

• Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible AsthmaCompletedNCT01099722Phase 3

  Sponsor listed in the registry: Mundipharma Research Limited

• Study of FLUTIFORM® VS Seretide® in Paediatric Subjects With AsthmaCompletedNCT00475813Phase 3

  Sponsor listed in the registry: Mundipharma Research Limited

• Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate AsthmaCompletedNCT00995800Phase 2

  Sponsor listed in the registry: Mundipharma Research Limited

• A Study to Assess the Safety and Tolerability of Oxycodone Hydrochloride 50mg/mL Administered as an InfusionTerminatedNCT00626600Phase 3

  Sponsor listed in the registry: Mundipharma Research Limited

• An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible AsthmaCompletedNCT00563056Phase 3

  Sponsor listed in the registry: Mundipharma Research Limited

• A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in AsthmaCompletedNCT02753712Phase 3

  Sponsor listed in the registry: Mundipharma Research Limited

• A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.TerminatedNCT01289223Phase 3

  Sponsor listed in the registry: Mundipharma Research Limited

• A Study of Whether 3 New Oral Formulations of a Strong Pain Killer Release the Same Amount of Drug Into the Body as the Marketed MedicationCompletedNCT02446561Phase 1

  Sponsor listed in the registry: Mundipharma Research Limited

• Flutiform® Compared With Seretide® in the Treatment of COPDCompletedNCT02195375Phase 2/3

  Sponsor listed in the registry: Mundipharma Research Limited

• A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated EosinophilsTerminatedNCT02693769Phase 2/3

  Sponsor listed in the registry: Mundipharma Research Limited

• Study to Assess Pharmacokinetic (PK), Bioavailability & Food Effect of MR902 Compared With Immediate Release (IR) Morphine Sulphate Oral SolutionCompletedNCT02773316Phase 1

  Sponsor listed in the registry: Mundipharma Research Limited

• An Assessment of Buprenorphine Transdermal Delivery System (BTDS) Patch AdhesionCompletedNCT02431624Phase 1

  Sponsor listed in the registry: Mundipharma Research Limited

• Bioequivalence and Adhesion Comparison of Buprenorphine PatchesCompletedNCT02268422Phase 1

  Sponsor listed in the registry: Mundipharma Research Limited

• A Study of Whether 2 New Oral Formulations of a Strong Pain Killer Release the Same Amount of Drug Into the Body as the Marketed MedicationCompletedNCT02089581Phase 1

  Sponsor listed in the registry: Mundipharma Research Limited

• A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy VolunteersCompletedNCT02403713Phase 1

  Sponsor listed in the registry: Mundipharma Research Limited

• A Dose Proportionality and Bioavailability Assessment of Buprenorphine Transdermal Delivery System Second Generation PatchesCompletedNCT02160067Phase 1

  Sponsor listed in the registry: Mundipharma Research Limited

• A Study to Assess How the Body Processes a Strong Painkiller When it is Given Alongside a Drug That Counteracts the Side Effects of Strong Painkillers in a Fasted and Fed State.CompletedNCT02133820Phase 1

  Sponsor listed in the registry: Mundipharma Research Limited

• Prospective Study on the Use of Transdermal Analgesic Buprenorphine Patches for Chronic Pain in the UKCompletedNCT01225861

  Sponsor listed in the registry: Mundipharma Research Limited

• Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.CompletedNCT00854867Phase 1

  Sponsor listed in the registry: Mundipharma Research Limited

• A Study Assessing Patient Handling of Flutiform® Breath-Actuated Inhaler (BAI) and Flutiform® Pressurised Metered Dose Inhaler (pMDI)CompletedNCT01739387

  Sponsor listed in the registry: Mundipharma Research Limited

• Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.TerminatedNCT00742495Phase 1/2

  Sponsor listed in the registry: Mundipharma Research Limited

• Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic LeukemiaTerminatedNCT00646165Phase 1

  Sponsor listed in the registry: Mundipharma Research Limited